Yoshida Masataka, Takazono Takahiro, Tashiro Masato, Saijo Tomomi, Morinaga Yoshitomo, Yamamoto Kazuko, Nakamura Shigeki, Imamura Yoshifumi, Miyazaki Taiga, Sawai Toyomitsu, Nishino Tomoya, Izumikawa Koichi, Yanagihara Katsunori, Mukae Hiroshi, Kohno Shigeru
The Second Department of Internal Medicine, Nagasaki University Hospital, Japan.
Intern Med. 2016;55(21):3211-3214. doi: 10.2169/internalmedicine.55.6787. Epub 2016 Nov 1.
Streptococcal toxic shock syndrome caused by group B streptococcus (GBS) is a rare, but lethal disease. We experienced a 45-year-old woman with pustular psoriasis who developed toxic shock-like syndrome during infliximab treatment. Surprisingly, similar episodes recurred three times in one year with restarting of infliximab treatments. In the third episode, GBS were detected in blood, urine, and vaginal secretion cultures. These episodes of shock syndrome were possibly due to GBS. To the best of our knowledge, this is the first case report of recurrent streptococcal toxic shock syndrome possibly caused by GBS which was induced by anti-TNF-α inhibitor therapy. The restarting of biological agents in patients with a history of toxic shock syndrome should therefore be avoided as much as possible.
由B组链球菌(GBS)引起的链球菌中毒性休克综合征是一种罕见但致命的疾病。我们遇到一名45岁脓疱型银屑病女性患者,在英夫利昔单抗治疗期间发生了中毒性休克样综合征。令人惊讶的是,在英夫利昔单抗治疗重新开始后的一年内类似发作复发了三次。在第三次发作时,血液、尿液和阴道分泌物培养物中检测到GBS。这些休克综合征发作可能归因于GBS。据我们所知,这是首例可能由抗TNF-α抑制剂治疗诱发GBS导致的复发性链球菌中毒性休克综合征病例报告。因此,应尽可能避免有中毒性休克综合征病史的患者重新使用生物制剂。